Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05447676 · ClinicalTrials.gov registry record · Early Phase 1
Effects of 4-AP on Functional SCI Recovery
A Early Phase 1 study, sponsored by Shirley Ryan AbilityLab.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 26
- Enrollment target
NCT05447676 is a Early Phase 1 study that has completed, run by Shirley Ryan AbilityLab. The registered enrollment target is 26 participants.
The verdict
NCT05447676, a Early Phase 1 study, has completed, sponsored by Shirley Ryan AbilityLab.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.
Interventions
- BEHAVIORAL Exercise training
- DRUG Dalfampridine
- OTHER STDP stimulation
- OTHER Placebo drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2022-06-30 |
| Est. Completion | 2025-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05447676
The ClinicalTrials.gov registry entry for NCT05447676 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shirley Ryan AbilityLab, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Exercise training is the first listed.
NCT05447676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05447676 about?
NCT05447676 is a clinical study titled "Effects of 4-AP on Functional SCI Recovery". The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP ...
What is the current status of trial NCT05447676?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 26 participants. The study started on 2022-06-30. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT05447676?
The interventions under investigation include: Exercise training (BEHAVIORAL), Dalfampridine (DRUG), STDP stimulation (OTHER), Placebo drug (OTHER).
Who is sponsoring clinical trial NCT05447676?
This trial is sponsored by Shirley Ryan AbilityLab, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.